181 related articles for article (PubMed ID: 24731702)
21. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
Hannes S; Abhari BA; Fulda S
Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
[TBL] [Abstract][Full Text] [Related]
22. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner.
Probst BL; Liu L; Ramesh V; Li L; Sun H; Minna JD; Wang L
Cell Death Differ; 2010 Oct; 17(10):1645-54. PubMed ID: 20431601
[TBL] [Abstract][Full Text] [Related]
23. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
24. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
[TBL] [Abstract][Full Text] [Related]
25. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase.
Giagkousiklidis S; Vogler M; Westhoff MA; Kasperczyk H; Debatin KM; Fulda S
Cancer Res; 2005 Nov; 65(22):10502-13. PubMed ID: 16288043
[TBL] [Abstract][Full Text] [Related]
26. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
27. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
28. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
29. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles.
Qian C; Wang Y; Chen Y; Zeng L; Zhang Q; Shuai X; Huang K
Biomaterials; 2013 Aug; 34(26):6175-84. PubMed ID: 23721794
[TBL] [Abstract][Full Text] [Related]
30. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
32. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
33. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.
Dai Y; Lawrence TS; Xu L
Am J Transl Res; 2009; 1(1):1-15. PubMed ID: 19966933
[TBL] [Abstract][Full Text] [Related]
34. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ
Pati ML; Niso M; Spitzer D; Berardi F; Contino M; Riganti C; Hawkins WG; Abate C
Eur J Med Chem; 2018 Jan; 144():359-371. PubMed ID: 29287249
[TBL] [Abstract][Full Text] [Related]
36. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.
Makvandi M; Tilahun ED; Lieberman BP; Anderson RC; Zeng C; Xu K; Hou C; McDonald ES; Pryma DA; Mach RH
Biochem Biophys Res Commun; 2015 Nov; 467(4):1070-5. PubMed ID: 26453012
[TBL] [Abstract][Full Text] [Related]
37. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
Sun H; Lu J; Liu L; Yang CY; Wang S
ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
[TBL] [Abstract][Full Text] [Related]
38. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
39. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
[TBL] [Abstract][Full Text] [Related]
40. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer.
Gilmour AM; Abdulkhalek S; Cheng TS; Alghamdi F; Jayanth P; O'Shea LK; Geen O; Arvizu LA; Szewczuk MR
Cell Signal; 2013 Dec; 25(12):2587-603. PubMed ID: 23993964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
